Ayşenur Özderya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ayşenur Özderya has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Kadriye Aydin
Kartal Lutfi Kirdar Research and Training Hospital
3 shared publications - Sule Temizkan
Department of Endocrinology, Baskent University İstanbul Medical Research and Practice Center, Istanbul, TUR
3 shared publications Temizkan
2 shared publicationsAyd
1 shared publication- Aylin Ege Gül
Pathology Clinic, Kartal Dr. Lütfi Kırdar City Hospital, İstanbul, Türkiye
1 shared publication - Burcu Hacıoğlu
Department of Internal Medicine, Haseki Education and Research Hospital, University of Health Sciences, Istanbul, Turkey
1 shared publication
Latest Publications
- Open Access
- 19 May 2025
- Published by Springer Nature in Bratislava Medical Journal
- p. 1-7
Neurosteroids, Anxiety and Quality of Life in Acromegaly
Objective: Acromegaly reduces quality of life. Neurosteroids can impact neuropsychological status and anxiety, but their effects on anxiety in acromegaly cases and quality of life are unclear. This study aims to evaluate the relationship between neurosteroids, anxiety, and quality of life in acromegaly patients. Design: This study included 33 cases in the acromegaly group (AG) and 30 healthy subjects in the control group (CG). Beck Anxiety Inventory (BAI) and Short Form-36 (SF-36) were used to assess anxiety levels and Quality of Life (QoL), respectively. The research assessed how anxiety and quality of life scores correlate with the concentrations of growth hormone, IGF-1, and specific neurosteroids (Allopregnanolone (AP), pregnenolone (PRG), 24S-hydroxycholesterol (24OHC), dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS), androsterone (ADT)). Results: AG had significantly higher BAI scores in comparison to CG. The SF-36 subdomain scores of general health, physical functioning, role limitations due to physical health, energy/fatigue, emotional well-being, social functioning, and pain were significantly lower in the AG. Conclusion: Neurosteroids may affect the quality of life and be associated with depression and anxiety levels in acromegaly.
- 19 May 2025
- Published by Springer Nature in Bratislava Medical Journal
- p. 1-7
Open AccessNeurosteroids, Anxiety and Quality of Life in Acromegaly
Objective: Acromegaly reduces quality of life. Neurosteroids can impact neuropsychological status and anxiety, but their effects on anxiety in acromegaly cases and quality of life are unclear. This study aims to evaluate the relationship between neurosteroids, anxiety, and quality of life in acromegaly patients. Design: This study included 33 cases in the acromegaly group (AG) and 30 healthy subjects in the control group (CG). Beck Anxiety Inventory (BAI) and Short Form-36 (SF-36) were used to assess anxiety levels and Quality of Life (QoL), respectively. The research assessed how anxiety and quality of life scores correlate with the concentrations of growth hormone, IGF-1, and specific neurosteroids (Allopregnanolone (AP), pregnenolone (PRG), 24S-hydroxycholesterol (24OHC), dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS), androsterone (ADT)). Results: AG had significantly higher BAI scores in comparison to CG. The SF-36 subdomain scores of general health, physical functioning, role limitations due to physical health, energy/fatigue, emotional well-being, social functioning, and pain were significantly lower in the AG. Conclusion: Neurosteroids may affect the quality of life and be associated with depression and anxiety levels in acromegaly.
- Open Access
- 15 December 2021
- Published by Springer Nature in Cureus
- Vol. 13 (12) , e20435
New Anthropometric Measurements: Relationship to Thyroid Functions in Euthyroid Obese Subjects
Body mass index (BMI) is unable to make a distinction between muscle mass and fat mass. Therefore, new anthropometric measurements, such as a body shape index (ABSI), body round index (BRI), and body adiposity index (BAI), have been formulated in recent years. Many studies have reported a correlation between BMI and thyroid function. In this study, we aimed to investigate the relationship between the above-mentioned new anthropometric measurements and thyroid functions in euthyroid obese subjects. We included 675 euthyroid (TSH ≥ 0.4 and < 4.5 mIU/l) individuals from the obesity outpatient clinic, aged between 18 and 65 years old, with BMI ≥ 30. Thyroid-stimulating hormone (TSH), free T4 (fT4) and free T3 (fT3), anthropometric measurements (weight, height, and waist circumference), and bioelectric impedance analyses [percent body fat (PBF) and fat-free mass (FFM)] of individuals were measured and recorded. ABSI, BRI, and BAI were calculated with the data from these measurements. Anthropometric measurements were compared to thyroid function tests. Eighty percent of the subjects were female. The mean age and BMI were 38 ± 17 years and 38 ± 6 kg/m2, respectively. TSH was found to be negatively correlated with ABSI (p = 0.006) and positively correlated with BAI (p < 0.001), but a statistically significant relationship with BRI (p = 0.193) was not determined. Free T4 was not associated with any of the anthropometric measurements. While fT3 was determined to be positively correlated with ABSI (p = 0.008) and negatively correlated with PBF and BAI (p = 0.001, p = 0.002, respectively), no statistically significant relationship with fT3 and BRI was determined. TSH is positively correlated with measurements of adiposity such as BMI, PBF, BAI while indexes in which abdominal obesity increases, such as waist circumference (WC), waist-hip ratio (WHR), and ABSI, are correlated with fT3 levels.
- 15 December 2021
- Published by Springer Nature in Cureus
- Vol. 13 (12) , e20435
Open AccessNew Anthropometric Measurements: Relationship to Thyroid Functions in Euthyroid Obese Subjects
Body mass index (BMI) is unable to make a distinction between muscle mass and fat mass. Therefore, new anthropometric measurements, such as a body shape index (ABSI), body round index (BRI), and body adiposity index (BAI), have been formulated in recent years. Many studies have reported a correlation between BMI and thyroid function. In this study, we aimed to investigate the relationship between the above-mentioned new anthropometric measurements and thyroid functions in euthyroid obese subjects. We included 675 euthyroid (TSH ≥ 0.4 and < 4.5 mIU/l) individuals from the obesity outpatient clinic, aged between 18 and 65 years old, with BMI ≥ 30. Thyroid-stimulating hormone (TSH), free T4 (fT4) and free T3 (fT3), anthropometric measurements (weight, height, and waist circumference), and bioelectric impedance analyses [percent body fat (PBF) and fat-free mass (FFM)] of individuals were measured and recorded. ABSI, BRI, and BAI were calculated with the data from these measurements. Anthropometric measurements were compared to thyroid function tests. Eighty percent of the subjects were female. The mean age and BMI were 38 ± 17 years and 38 ± 6 kg/m2, respectively. TSH was found to be negatively correlated with ABSI (p = 0.006) and positively correlated with BAI (p < 0.001), but a statistically significant relationship with BRI (p = 0.193) was not determined. Free T4 was not associated with any of the anthropometric measurements. While fT3 was determined to be positively correlated with ABSI (p = 0.008) and negatively correlated with PBF and BAI (p = 0.001, p = 0.002, respectively), no statistically significant relationship with fT3 and BRI was determined. TSH is positively correlated with measurements of adiposity such as BMI, PBF, BAI while indexes in which abdominal obesity increases, such as waist circumference (WC), waist-hip ratio (WHR), and ABSI, are correlated with fT3 levels.
- 24 January 2019
- Published by Wiley in World Journal of Surgery
- Vol. 43 (5) , 1243-1248
Does Primary Hyperparathyroidism Have an Association with Thyroid Papillary Cancer? A Retrospective Cohort Study
Background: To investigate the relationship between primary hyperparathyroidism (pHPT) and papillary thyroid cancer (PTC).Methods: The perioperative findings of 275 patients with pHPT who underwent surgery between January 2014 and December 2017 were retrospectively reviewed. Thirty‐one patients were diagnosed with pHPT and PTC concurrently. Pathology results and demographic findings of these patients were compared with 186 patients who underwent thyroidectomy and diagnosed with PTC at the same time interval.Results: The co‐occurrence of pHPT and PTC was 11.3% (31/275). The median ages of the pHPT, pHPT + PTC, and PTC groups were 55, 57, and 50 years old, respectively (p < 0.001). The diameter of tumor was smaller in the pHPT + PTC group [median 7 mm (range 0.5–25 mm) vs. 15 mm (range 1–100 mm)], with higher rates of microcarcinomas (p < 0.001), than the patients in the PTC group. Examination of tumor morphology showed higher rates of tumor capsule invasion and multicentricity in the pHPT + PTC group than those in the isolated PTC group (p = 0.02, p = 0.04, respectively).Conclusion: The pHPT + PTC group had significantly smaller tumor diameter than the PTC group. This result may support the idea that pHPT leads to overdiagnosis of PTC. However, observation of high rates of tumor capsule invasion and multicentricity in the pHPT + PTC group may suggest an associative etiology with more aggressive PTC.
- 24 January 2019
- Published by Wiley in World Journal of Surgery
- Vol. 43 (5) , 1243-1248
Does Primary Hyperparathyroidism Have an Association with Thyroid Papillary Cancer? A Retrospective Cohort Study
Background: To investigate the relationship between primary hyperparathyroidism (pHPT) and papillary thyroid cancer (PTC).Methods: The perioperative findings of 275 patients with pHPT who underwent surgery between January 2014 and December 2017 were retrospectively reviewed. Thirty‐one patients were diagnosed with pHPT and PTC concurrently. Pathology results and demographic findings of these patients were compared with 186 patients who underwent thyroidectomy and diagnosed with PTC at the same time interval.Results: The co‐occurrence of pHPT and PTC was 11.3% (31/275). The median ages of the pHPT, pHPT + PTC, and PTC groups were 55, 57, and 50 years old, respectively (p < 0.001). The diameter of tumor was smaller in the pHPT + PTC group [median 7 mm (range 0.5–25 mm) vs. 15 mm (range 1–100 mm)], with higher rates of microcarcinomas (p < 0.001), than the patients in the PTC group. Examination of tumor morphology showed higher rates of tumor capsule invasion and multicentricity in the pHPT + PTC group than those in the isolated PTC group (p = 0.02, p = 0.04, respectively).Conclusion: The pHPT + PTC group had significantly smaller tumor diameter than the PTC group. This result may support the idea that pHPT leads to overdiagnosis of PTC. However, observation of high rates of tumor capsule invasion and multicentricity in the pHPT + PTC group may suggest an associative etiology with more aggressive PTC.
- 1 January 2017
- Published by Kare Publishing in Southern Clinics of Istanbul Eurasia
- Vol. 28 (2)
Evaluation Of The Relationship Between İnsülin Resistance And Selenoprotein P İn Patients With Polycystic Ovary Syndrome
- 1 January 2017
- Published by Kare Publishing in Southern Clinics of Istanbul Eurasia
- Vol. 28 (2)
Evaluation Of The Relationship Between İnsülin Resistance And Selenoprotein P İn Patients With Polycystic Ovary Syndrome
- 1 January 2015
- Published by Elsevier in Endocrine Practice
- Vol. 21 (1) , 23-29
Normocalcemic Hyperparathyroidism and Insulin Resistance
- 1 January 2015
- Published by Elsevier in Endocrine Practice
- Vol. 21 (1) , 23-29
Normocalcemic Hyperparathyroidism and Insulin Resistance